Skip to main content
Premium Trial:

Request an Annual Quote

Wearable Sensors May Predict Early Onset of Illness, Study Says

NEW YORK (360Dx) – During routine patient visits, physicians generally measure heart rate, blood pressure, and body temperature, but these parameters may need more frequent screening to achieve more effective results.

In a study, researchers at Stanford University School of Medicine said that wearable sensors may provide a viable solution. Published online Thursday in PLOS Biology, the paper demonstrates that wearable sensors that monitor heart rate, activity, skin temperature, and other variables can reveal inflammation, insulin resistance, and the onset of infection, even when a patient otherwise doesn't notice anything wrong.

Collecting nearly 2 billion measurements from 60 people, the researchers gathered continuous data from wearable biosensor devices, and periodic data about blood chemistry, gene expression, and other parameters from laboratory tests.

Each person wore several monitors so that the group could collect more than 250,000 measurements per day. They collected information about weight; heart rate; blood oxygen levels; and skin temperature. They also kept track of activities such as sleep; walking; the number of steps taken; biking and running; and other data including calories expended; acceleration; and exposure to gamma rays and X-rays.

The researchers noted that elevated heart rate and blood pressure are associated with cardiovascular disease, and elevated body temperature occurs during pathogen infection and inflammation. Their study demonstrated that by using wearables it is possible to monitor deviations from normal measurements and link them with environmental conditions, illness, or other factors that affect health.

Distinctive patterns of deviation from normal seem to correlate with health problems, and algorithms designed to detect these patterns of change could potentially contribute to clinical diagnostics and research, they added.

In a statement from Stanford, Michael Snyder, professor and chair of genetics at the university, and a study subject for the paper, said that sensors he wore detected changes in his heart rate and blood oxygen levels during a long flight to Norway. While his oxygen levels normally dropped during flights and while his heart rate increased at the start of flights, they would usually return to normal levels during the flight and after he landed.

However, at the end of this flight, that didn't happen.

Two weeks earlier, Snyder had been in rural Massachusetts and was concerned that he may have been bitten by a tick and infected with Lyme disease. He convinced a doctor in Norway to prescribe him an antibiotic to treat the disease, and subsequent testing confirmed that Snyder had, indeed, been infected with Lyme disease.

“Wearables helped make the initial diagnosis,” Snyder said in the university's statement.

Wearable sensors with diagnostic applications are taking steps toward commercialization.

In December 2016, for example, New York-based Nanowear became one of the few companies developing wearable diagnostic monitoring devices to receive regulatory clearance from the US Food and Drug Administration. The firm received 510(k) clearance for its first product, the SimplECG medical-grade cardiac vest, which collects electrocardiogram, heart rate, and respiratory rate data from nanosensors embedded in the garment and transfers it to a web-based portal for review by a physician.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.